News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
How HIV works
Newly identified natural protein blocks HIV, other deadly viruses

A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.

Published
12 February 2013
From
UCLA press release
New and experimental HIV treatments
ViiV announces halt to lersivirine development

On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.

Published
07 February 2013
From
HIVandHepatitis.com
New and experimental HIV treatments
Innovative HIV Gene Therapy Study Soon to Start Enrollment

Calimmune, a small biotechnology company, has been given the go-ahead by the U.S. Food and Drug Administration to start enrolling HIV-infected people in a first-of-its-kind gene therapy study that will modify two HIV attachment sites in CD4+ cells.

Published
06 February 2013
From
TheBody.com
New and experimental HIV treatments
Suboptimal Suppression with Maraviroc plus a Boosted Protease Inhibitor?

Until larger studies are done, such regimens are probably best avoided.

Published
05 February 2013
From
Journal Watch
New and experimental HIV treatments
Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV

The Phase 3 studies will examine a once-daily single tablet regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg compared to Gilead’s Stribild®(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among patients new to HIV therapy.

Published
25 January 2013
From
Gilead press release
Pharmaceutical industry
Gilead petitions FDA over its Stribild AIDS med

In a challenge to FDA decisionmaking that will be closely watched by the pharmaceutical industry, Gilead Sciences has asked the agency to grant five years of exclusivity to its recently approved Stribild AIDS medication.

Published
25 January 2013
From
Pharmalot
The search for a cure
Pitt team finds 'Achilles Heel' of key HIV replication protein

Previous research demonstrated that a small HIV protein called Nef interacts with many other proteins in infected cells to help the virus multiply and hide from the immune system. The Pitt group developed a way to track Nef activity in high-throughput drug screening protocols by linking it to an enzyme called Hck, which is activated by Nef in HIV-infected cells.

Published
25 January 2013
From
Eurekalert (press release)
The search for a cure
Stanford lab creates HIV-resistant cells

Stanford scientists have developed a technique to genetically engineer certain immune cells and make them resistant to HIV - a technique that, if proved successful in human subjects, could provide an alternative to the lifetime of medication that people with HIV infections now face.

Published
23 January 2013
From
San Francisco Chronicle
Outcomes and prognosis
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
New and experimental HIV treatments
Researchers attack HIV's final defenses before drug-resistant mutations emerge

The scientists are developing new compounds designed to target an enzyme in HIV called RNase H, which has escaped the reach of existing drugs.

Published
17 January 2013
From
Medical Xpress
← Prev12345...66Next →

Filter by country